Antibodies to myostatin

Details Antibodies to myostatin Antibodies to myostatin

2006-04-24

2010-10-05

Bristol, Lynn (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C530S388250

Reexamination Certificate

active

07807159

ABSTRACT:
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4634665 (1987-01-01), Axel et al.
patent: 4740461 (1988-04-01), Kaufman
patent: 4912040 (1990-03-01), Kaufman et al.
patent: 4959455 (1990-09-01), Clark et al.
patent: 5151510 (1992-09-01), Stec et al.
patent: 5179017 (1993-01-01), Axel et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5612205 (1997-03-01), Kay et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643763 (1997-07-01), Dunn et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5721367 (1998-02-01), Kay et al.
patent: 5741957 (1998-04-01), Deboer et al.
patent: 5750172 (1998-05-01), Meade et al.
patent: 5756687 (1998-05-01), Denman et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5959177 (1999-09-01), Hein et al.
patent: 5985615 (1999-11-01), Jakobovits et al.
patent: 5998209 (1999-12-01), Jokobovits et al.
patent: 6046037 (2000-04-01), Hiatt et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6091001 (2000-07-01), Jakobovits et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6130364 (2000-10-01), Jakobovits et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6210670 (2001-04-01), Berg
patent: 6417429 (2002-07-01), Hein et al.
patent: 6517529 (2003-02-01), Quinn
patent: 2003/0138422 (2003-07-01), Aghajanian et al.
patent: 2006/0030522 (2006-02-01), Knopf et al.
patent: 2007/0178095 (2007-08-01), Smith et al.
patent: WO 91/10741 (1991-07-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 98/16654 (1998-04-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 99/45031 (1999-09-01), None
patent: WO 99/53049 (1999-10-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 00/37504 (2000-06-01), None
patent: WO 2004/037861 (2004-05-01), None
patent: WO 2004/108157 (2004-12-01), None
patent: WO 2005/094446 (2005-10-01), None
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. (2002) J. Mol. Biol. 320, 415-428.
Holm et al (2007) Mol. Immunol. 44: 1075-1084.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Smith-Gill et al. (J. Immunol. 139:4135-4144 (1987)).
Kumar et al. (J. Biol. Chem. 275:35129-35136 (2000)).
Song et al. (Biochem Biophys Res Comm 268:390-394 (2000)).
Bost et al. (Immunol. Invest. (1988) 17:577-586).
Bendayan (J. Histochem. Cytochem. (1995) 43:881-886).
Campbell et al, Biology, 5th ed. p. 856, 1999.
Search output from ATCC website for query regarding: 1—116—1 (PTA-6566); 1—132—1 (PTA-6567); 1—136—3 (PTA-6568); 1—257—1 (PTA-6569); 1—268—1 (PTA-6570); 1—314—1 (PTA-6571); 1—46—1 (PTA-6572); 1—66—1 (PTA-6573); 2—112—1 (PTA-6574); 2—43—1 (PTA-6575); and 2—177—1 (PTA-6576), (Nov. 1, 2007).
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
MacCallum et al. (J. Mol. Biol. (1996) 262:732-745).
Babcook, J.S. et al. “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities,”Proc. Natl. Acad. Sci. USA93:7843-48 (1996).
Bird et al., “Single-chain antigen-binding proteins,”Science, 242:423-426 (1988).
Gonnet et al., “Exhaustive matching of the entire protein sequence database,”Science, 256:1443-45 (1992).
Gonzalez-Cadavid et al., “Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting,”Proc. Natl. Acad. Sci., 95 14938-4321 (1998).
Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,”Nature Genetics, 7:13-21 (1994).
Green and Jakobovits, “Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes,”Journal of Experimental Medicine, 188(3):483-495 (1998).
Griffiths et al., “Human anti-self antibodies with high specificity from phage display libraries,”The EMBO Journal, 12(2):725-734 (1993).
Griffiths et al., “Isolation of high affinity human antibodies directly from large synthetic repertoires,”The EMBO Journal, 13:3245-3260 (1994).
Hamrick et al., “Bone Architecture and Disc Degeneration in the Lumbar Spine of Mice Lacking GDF-8 (Myostatin),”J. Orthopaedic Res. 21:1025-1032 (2003).
Hill et al., “The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum,”J. Biol. Chem. 277:40735-40741 (2002).
Hill et al., “Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains,”Mol. Endocrin17(6): 1144-1154 (2003).
Holliger et al., “Diabodies: small bivalent and bispecific antibody fragments,”Proc. Natl. Acad. Sci., 90:6444-6448 (1993).
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli,” Proc. Natl. Acad. Sci., 85:5879-5883 (1988).
Ill et al., “Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions,”Protein Engineering, 10(8):949-957 (1997).
Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers,”J. Immunol. 148:1547-1553 (1992).
LaPlanche et al., “Phosphorothioate-modified oligodeoxyribonucleotides, III. NMR and UV spectroscopic studies of the Rp-Rp, Sp-Sp, and Rp-Spduplexes, [d(GG5AATTCC)]2, derived from diastereomeric O-ethyl phosphorothioates,”Nucleic Acids Research, 14(22):9081-9093 (1986).
Li

Affiliated with

Also associated with

Rating

Antibodies to myostatin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to myostatin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to myostatin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4164528